Patents by Inventor Lorna Mitchell

Lorna Mitchell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS FOR ACTIVATING PYRUVATE KINASE
    Publication number: 20210017184
    Abstract: Compositions for the activation of PKR are provided, as well as therapeutic administration of the compositions for the treatment of pyruvate kinase-related medical conditions, such as pyruvate kinase deficiency (PKD).
    Type: Application
    Filed: October 2, 2020
    Publication date: January 21, 2021
    Inventors: Xiaozhang Zheng, Neal Green, Gary Gustafson, David R. Lancia, JR., Lorna Mitchell, Tatiana Shelekhin
  • TREATING SICKLE CELL DISEASE WITH A PYRUVATE KINASE R ACTIVATING COMPOUND
    Publication number: 20200405699
    Abstract: Compounds that activate pyruvate kinase R can be used for the treatment of sickle cell disease (SCD). Methods and compositions for the treatment of SCD are provided herein, including a therapeutic compound designated as Compound 1.
    Type: Application
    Filed: September 1, 2020
    Publication date: December 31, 2020
    Inventors: Anna ERICSSON, Neal GREEN, Gary GUSTAFSON, David R. LANCIA, Jr., Gary MARSHALL, Lorna MITCHELL, David RICHARD, Zhongguo WANG, Sanjeev FORSYTH, Patrick F. KELLY, Madhu MONDAL, Maria RIBADENEIRA, Patricia SCHROEDER
  • Compositions for activating pyruvate kinase
    Patent number: 10836771
    Abstract: Compositions for the activation of PKR are provided, as well as therapeutic administration of the compositions for the treatment of pyruvate kinase-related medical conditions, such as pyruvate kinase deficiency (PKD).
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: November 17, 2020
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Xiaozhang Zheng, Neal Green, Gary Gustafson, David R. Lancia, Jr., Lorna Mitchell, Tatiana Shelekhin
  • ACTIVATING PYRUVATE KINASE R
    Publication number: 20200253939
    Abstract: This disclosure provides compounds and compositions for activating pyruvate kinase R (PKR) and related methods of manufacturing and using these compounds and compositions.
    Type: Application
    Filed: May 1, 2020
    Publication date: August 13, 2020
    Inventors: Anna Ericsson, Neal Green, Gary Gustafson, David R. Lancia, Gary Marshall, Lorna Mitchell, David Richard, Zhongguo Wang
  • Activating pyruvate kinase R
    Patent number: 10675274
    Abstract: This disclosure provides compounds and compositions for activating pyruvate kinase R (PKR) and related methods of manufacturing and using these compounds and compositions.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: June 9, 2020
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Anna Ericsson, Neal Green, Gary Gustafson, David R. Lancia, Jr., Gary Marshall, Lorna Mitchell, David Richard, Zhongguo Wang
  • TREATING SICKLE CELL DISEASE WITH A PYRUVATE KINASE R ACTIVATING COMPOUND
    Publication number: 20200129485
    Abstract: Compounds that activate pyruvate kinase R can be used for the treatment of sickle cell disease (SCD). Methods and compositions for the treatment of SCD are provided herein, including a therapeutic compound designated as Compound 1.
    Type: Application
    Filed: September 19, 2019
    Publication date: April 30, 2020
    Inventors: Anna Ericsson, Neal Green, Gary Gustafson, David R. Lancia, JR., Gary Marshall, Lorna Mitchell, David Richard, Zhongguo Wang, Forsyth Sanjeev, Kelly J. Patrick, Madhu Mondal, Maria Ribadeneira, Schroeder Patricia
  • ACTIVATING PYRUVATE KINASE R AND MUTANTS THEREOF
    Publication number: 20200087309
    Abstract: The disclosure provides chemical compounds useful as activators of PKR. PKR activating compounds are useful in the treatment of disease and disorders associated with modulation of PKR and/or PKM2, such as pyruvate kinase deficiency (PKD).
    Type: Application
    Filed: September 19, 2019
    Publication date: March 19, 2020
    Inventors: David R. Lancia, JR., Gary Gustafson, Neal Green, Lorna Mitchell, Anna Ericsson, David Richard
  • ACTIVATING PYRUVATE KINASE R
    Publication number: 20200085798
    Abstract: This disclosure provides compounds and compositions for activating pyruvate kinase R (PKR) and related methods of manufacturing and using these compounds and compositions.
    Type: Application
    Filed: September 19, 2019
    Publication date: March 19, 2020
    Inventors: Anna Ericsson, Neal Green, Gary Gustafson, David R. Lancia, JR., Gary Marshall, Lorna Mitchell, David Richard, Zhongguo Wang
  • PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS
    Publication number: 20200069643
    Abstract: The disclosure relates to modulating pyruvate kinase and provides novel chemical compounds of formula (I) useful as activators of PKR, as well as various uses of these compounds. PKR activating compounds are useful in the treatment of diseases and disorders associated with PKR and/or PKM2, such as pyruvate kinase deficiency (PKD), sickle cell disease (SCD), and thalassemia.
    Type: Application
    Filed: March 20, 2018
    Publication date: March 5, 2020
    Inventors: Anna ERICSSON, Neal GREEN, Gary GUSTAFSON, Bingsong HAN, David R. LANCIA, Jr., Lorna MITCHELL, David RICHARD, Tatiana SHELEKHIN, Chase C. SMITH, Zhongguo WANG, Xiaozhang ZHENG
  • COMPOSITIONS FOR ACTIVATING PYRUVATE KINASE
    Publication number: 20200031839
    Abstract: Compositions for the activation of PKR are provided, as well as therapeutic administration of the compositions for the treatment of pyruvate kinase-related medical conditions, such as pyruvate kinase deficiency (PKD).
    Type: Application
    Filed: October 4, 2019
    Publication date: January 30, 2020
    Inventors: Xiaozhang Zheng, Neal Green, Gary Gustafson, David R. Lancia, JR., Lorna Mitchell, Tatiana Shelekhin
  • Compositions for activating pyruvate kinase
    Patent number: 10472371
    Abstract: Compositions for the activation of PKR are provided, as well as therapeutic administration of the compositions for the treatment of pyruvate kinase-related medical conditions, such as pyruvate kinase deficiency (PKD).
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: November 12, 2019
    Assignee: FORMA THERAPEUTICS, INC.
    Inventors: Xiaozhang Zheng, Neal Green, Gary Gustafson, David R. Lancia, Jr., Lorna Mitchell, Tatiana Shelekhin
  • COMPOSITIONS FOR ACTIVATING PYRUVATE KINASE
    Publication number: 20190218221
    Abstract: Compositions for the activation of PKR are provided, as well as therapeutic administration of the compositions for the treatment of pyruvate kinase-related medical conditions, such as pyruvate kinase deficiency (PKD).
    Type: Application
    Filed: January 11, 2019
    Publication date: July 18, 2019
    Inventors: Xiaozhang Zheng, Neal Green, Gary Gustafson, David R. Lancia, JR., Lorna Mitchell, Tatiana Shelekhin
  • Compositions for activating pyruvate kinase
    Patent number: 10208052
    Abstract: Compositions for the activation of PKR are provided, as well as therapeutic administration of the compositions for the treatment of pyruvate kinase-related medical conditions, such as pyruvate kinase deficiency (PKD).
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: February 19, 2019
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Xiaozhang Zheng, Neal Green, Gary Gustafson, David R. Lancia, Jr., Lorna Mitchell, Tatiana Shelekhin
  • ESTROGEN MODULATORS
    Publication number: 20070149564
    Abstract: The present application is directed to a new class of isoxazoles and their use as estrogen modulators.
    Type: Application
    Filed: December 19, 2006
    Publication date: June 28, 2007
    Applicant: PFIZER INC.
    Inventors: Simon Bailey, Stephen Barrett, Larry Bratton, Stephen Fakhoury, Sandra Jennings, Lorna Mitchell, Raj Raheja, Veerabahu Shanmugasundaram
  • [B]-fused bicyclic proline derivatives and their use for treating arthritic conditions
    Publication number: 20050143427
    Abstract: This invention relates to a compound which is [b]-fused bicyclic proline derivative, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition comprising the compound or the salt thereof, and methods of treating diseases, including, but not limited to, methods of preventing or inhibiting joint cartilage damage and preventing or treating diseases characterized by joint cartilage damage, joint inflammation, or joint pain. The [b]-fused bicyclic proline derivatives are compounds of Formula I as described above. Diseases characterized by joint cartilage damage or joint pain include, for example, osteoarthritis and rheumatoid arthritis. Rheumatoid arthritis is also characterized by joint inflammation. This invention also relates to methods of synthesizing and preparing the [b]-fused bicyclic proline derivatives, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 12, 2004
    Publication date: June 30, 2005
    Inventors: Nicole Barvian, Cleo Connolly, Peter Guzzo, James Hamby, James Hicks, Matthew Johnson, Van-Duc Le, Lorna Mitchell, William Roark
  • plant named ‘RobloM’
    Patent number: PP21203
    Abstract: A new and distinct Clematis cultivar named ‘RobloM’ is disclosed, characterized by having distinctive flower coloration, with an unusual white bar on a background of purple/pink. Additionally, the new variety characteristically blooms very early and has a very rapid growth habit. The new variety is a Clematis, normally produced as an outdoor garden or container plant.
    Type: Grant
    Filed: January 8, 2009
    Date of Patent: August 17, 2010
    Inventors: Robinson Charles Mitchell, Lorna Mitchell